Cephalexin
- Generic Name
- Cephalexin
- Brand Names
- Keflex
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N3O4S
- CAS Number
- 15686-71-2
- Unique Ingredient Identifier
- 5SFF1W6677
- Background
Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis. Cephalexin was approved by the FDA on 4 January 1971.
- Indication
Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria. These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.
- Associated Conditions
- Bone Infection, Genitourinary tract infection, Otitis Media (OM), Respiratory Tract Infections (RTI), Skin and skin structure infections, Acute Prostatitis
Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis
- Conditions
- Pyelonephritis Acute
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Brett A Faine
- Target Recruit Count
- 40
- Registration Number
- NCT06127160
- Locations
- 🇺🇸
Olive View - UCLA Medical Center, Sylmar, California, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Antibiotic Prophylaxis in Pediatric Open Fractures
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 800
- Registration Number
- NCT06055712
- Locations
- 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
High-dose Cephalexin for Cellulitis (HI-DOCC)
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 446
- Registration Number
- NCT05852262
- Locations
- 🇨🇦
South Health Campus, Calgary, Alberta, Canada
🇨🇦Queen Elisabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦Kingston Health Sciences Centre, Kingston, Ontario, Canada
The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- Other: Standard of care treatment of tuberculosisDrug: Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Western Sydney Local Health District
- Target Recruit Count
- 30
- Registration Number
- NCT05664568
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Sydney, Australia
🇦🇺Western Sydney Health District, Sydney, Australia
🇦🇺Blacktown Hospital, Sydney, Australia
Role of Prophylactic Postoperative Antibiotics in HoLEP
- Conditions
- Urinary Tract InfectionsBenign Prostatic Hyperplasia
- Interventions
- Procedure: Holmium Laser Enucleation of prostate
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 100
- Registration Number
- NCT05274672
- Locations
- 🇺🇸
Einstein Healthcare network, Philadelphia, Pennsylvania, United States
🇺🇸Baylor Scott and White, Temple, Texas, United States
Microbiome and Association With Implant Infections
- Conditions
- Breast Cancer FemaleGenetic Predisposition to DiseaseBreast Cancer
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 200
- Registration Number
- NCT05020574
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Oral Amoxicillin and Cephalexin PK/PD in Neonates
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 60
- Registration Number
- NCT04916951
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children
- Conditions
- InfectionPediatric Infectious DiseaseComplicated Urinary Tract Infection
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 452
- Registration Number
- NCT04876131
- Locations
- 🇦🇺
Women and Children's Hospital, Adelaide, South Australia, Australia
🇦🇺Monash Health, Melbourne, Victoria, Australia
🇦🇺Royal Children's Hospital, Parkville, Victoria, Australia
Postoperative Antibiotics Following Primary and Secondary Breast Augmentation
- Conditions
- Surgical Site InfectionCapsular Contracture Associated With Breast ImplantAntibiotic Resistant InfectionAntibiotic Side Effect
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT04834310
SSI Rates in Patients Undergoing Mastectomy Without Reconstruction- A Multicenter, Double-blinded RCT.
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 384
- Registration Number
- NCT04577846
- Locations
- 🇵🇰
Aga Khan University Hospital, Karachi, Sindh, Pakistan
🇵🇰Dow University of Health Sciences, Karachi, Sindh, Pakistan
🇵🇰Liaquat National Hospital, Karachi, Sindh, Pakistan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.